SCOPE FLUIDICS SA ZY-10 (S84) - Total Liabilities
Based on the latest financial reports, SCOPE FLUIDICS SA ZY-10 (S84) has total liabilities worth €33.50 Million EUR (≈ $39.17 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore SCOPE FLUIDICS SA ZY-10 equity growth rate to track the company's year-over-year net asset growth rate.
SCOPE FLUIDICS SA ZY-10 - Total Liabilities Trend (2021–2025)
This chart illustrates how SCOPE FLUIDICS SA ZY-10's total liabilities have evolved over time, based on quarterly financial data.
SCOPE FLUIDICS SA ZY-10 Competitors by Total Liabilities
The table below lists competitors of SCOPE FLUIDICS SA ZY-10 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shotspotter Inc
NASDAQ:SSTI
|
USA | $63.58 Million |
|
Daemyung Sonoseason Co.Ltd
KQ:007720
|
Korea | ₩54.13 Billion |
|
BCP Investment Corp.
NASDAQ:BCIC
|
USA | $350.91 Million |
|
Gan Shmuel
TA:GSFI
|
Israel | ILA73.39 Million |
|
Dwarikesh Sugar Industries Limited
NSE:DWARKESH
|
India | Rs4.69 Billion |
|
iCapital.biz Berhad
KLSE:5108
|
Malaysia | RM462.00K |
|
Ganesh Benzoplast Limited
NSE:GANESHBE
|
India | Rs1.81 Billion |
|
Empire State Realty OP LP ES
NYSE:ESBA
|
USA | $2.58 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down SCOPE FLUIDICS SA ZY-10's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of SCOPE FLUIDICS SA ZY-10.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SCOPE FLUIDICS SA ZY-10's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SCOPE FLUIDICS SA ZY-10 (2021–2025)
The table below shows the annual total liabilities of SCOPE FLUIDICS SA ZY-10 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €33.50 Million ≈ $39.17 Million |
+26.34% |
| 2024-12-31 | €26.52 Million ≈ $31.00 Million |
+28.99% |
| 2023-12-31 | €20.56 Million ≈ $24.04 Million |
+55.96% |
| 2022-12-31 | €13.18 Million ≈ $15.41 Million |
-71.34% |
| 2021-12-31 | €45.99 Million ≈ $53.77 Million |
-- |
About SCOPE FLUIDICS SA ZY-10
Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.